A Trial to Determine Weight Gain Benefits of Caloric Supplementation for NAS Infants

Overview

A randomized clinical study in NAS infants managed via the Eat, Sleep, Console (ESC) approach comparing early weight loss on a standard-caloric density versus high-caloric density feeding regimen.

Full Title of Study: “A Randomized Control Trial to Determine Weight Gain Benefits of Caloric Supplementation for NAS Infants”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2025

Detailed Description

The aims of the study is to systematically evaluate the benefit of high-caloric diet regimens given to NAS infants in the first three weeks of life. Breastfeeding is the preferred feeding method for NAS infants as it has shown to reduce NAS severity and infant weight loss, though women who are not adherent to drug treatment programs or have the potential to use illicit drugs are not able to breastfeed due to the risks posed to the infant. Several studies have demonstrated the potential for caloric enhancement of formula and breast milk to support weight gain in NAS infants. Through a randomized control trial analyzing infant weight gain on standard-calorie vs. high-calorie diet regimens, we aim to quantify weight patterns in NAS infants and show that increasing caloric intake can improve weight gain.

Interventions

  • Dietary Supplement: High-calorie formula
    • Infant randomly assigned to high-calorie formula for 14 days

Arms, Groups and Cohorts

  • Experimental: High-calorie formula
    • Infant randomly assigned to high-calorie formula for 14 days
  • No Intervention: Standard calorie formula
    • Infant randomly assigned to standard-calorie formula for 14 days

Clinical Trial Outcome Measures

Primary Measures

  • Maximal percent weight loss compared to birth weight
    • Time Frame: 2 weeks
    • this will be measured by twice daily weights while in the hospital and once daily weights at home for two weeks after birth compared with birth weight

Secondary Measures

  • Hours to weight nadir
    • Time Frame: 2 weeks
    • Measured by determining the hours of life that the maximal percent weight loss was obtained for each patient, assessed within the first two weeks after birth
  • Days to return to birthweight
    • Time Frame: 1 month
    • Measured by determining the days of life each patient regained birthweight, assessed within the first month after birth
  • Percent weight change per day
    • Time Frame: 2 weeks
    • Measured by comparing the weight from the weight obtained the day prior, assessed daily for the first two weeks after birth
  • Length of hospital stay
    • Time Frame: up to 6.5 days
    • Measured by comparing admission time to discharge time, assessed at hospital discharge

Participating in This Clinical Trial

Infant Inclusion Criteria:

  • Infants with NAS born to mothers age 18-45 with methadone exposure before or during pregnancy who do not intend to place their infants for adoption – Infants > 2200 g Infants at least 36 weeks gestational age – Delivered at: Yale New Haven Hospital – Mothers/infants able to return to outpatient pediatric provider for 2 month and 4 month weights visits Infant Exclusion Criteria:

  • Infants with major congenital malformations – Infants enrolled to NICU >24 hours for medical conditions other than NAS treatment before 3 days of life Mother's Inclusion criteria - – Pregnant women (age 18-45) who have started methadone treatment at obstetrics or other YNHH appointments – Confirm methadone treatment is received from a licensed treatment program – Confirm that mothers are planning to deliver their infant(s) at Yale New Haven Hospital – Confirm that mothers do not intend to place the infant(s) for adoption – Confirm mother's willingness to participate in the study (including attending the 2-month and 4-month follow up weigh-ins with pediatrician) – Consent forms will be signed and faxed to study staff

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Yale University
  • Collaborator
    • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Matthew Grossman, MD, Principal Investigator, Yale University
  • Overall Contact(s)
    • Lisa Palmieri, BA, 203-785-4651, lisa.palmieri@yale.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.